LENSAR, Inc.
LNSRHealthcareNASDAQMedical Devices
Scan Results
Daily timeframePart of the healthcare sector, LENSAR, Inc. (LNSR) is listed under Medical Devices. The $105.7M market capitalization puts LNSR squarely in micro-cap range for its industry. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision.
Market Cap
$105.7M
Beta
0.97
P/E (TTM)
43.00
P/E (Fwd)
-12.11
EPS (TTM)
$0.20
EPS (Fwd)
$-0.71
ROE
357.3%
ROA
-18.7%
Cash
$13.6M
Total Debt
$2.4M
Free CF
-$24.4M
52W Change
-29.3%
Annual Financials
Cash vs Debt
Where LNSR stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, LNSR finished 15.65% above its 150-day moving average ($7.35) and 1.80% above its 200-day moving average ($8.35). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LNSR overbought or oversold?
At the September 3, 2026 close, LNSR's RSI(14) was 53.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
LENSAR, Inc. holds $13.6M in cash against $2.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$24.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at 357.3%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $35.4M (2022) to $58.4M (2025), reflecting a 65% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing LNSR.